Jena D. French
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jena D. French has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Bryan R. Haugen
Department of Medicine, University of Colorado Anschutz Medical Campus , Aurora, CO 80045
29 shared publications - Paul J. Norman
Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO, USA
24 shared publications - Ticiana Della Justina Farias
Department of Biomedical Informatics, University of Colorado School of Medicine
24 shared publications - Andrew G. Gianoukakis
David Geffen School of Medicine at UCLA, Los Angeles, California. 7
23 shared publications - Bhavana Konda
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and Arthur G. James Cancer Center , Columbus, OH 43210
23 shared publications - Daniel W. Bowles
Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO
23 shared publications
Latest Publications
- Open Access
- 22 November 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , e1289-e1301
Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific Proteins and Neo-antigens in Follicular Cell-derived Thyroid Cancers
Background: Thyroid cancers are among the growing list of cancer types that are resistant to immune-checkpoint inhibitor monotherapy. Although T-cell infiltration is common in follicular cell-derived thyroid cancers, tumor mutation burden is low. The antigenic potential of thyroid cancers is unknown. Methods: To investigate the anti-tumor T-cell response in thyroid cancer, we expanded tumor-infiltrating lymphocytes (TIL) from primary thyroid tumors and tumor-involved lymph nodes (TILN). Putative neoantigens and both tissue-associated and tumor-associated antigens were identified by targeted sequencing and RNA-seq. HLA typing was performed for all patients, and neoantigen binding potential was predicted for each patient using NetMHCpan 4.1 and NetMHCIIpan 4.0 algorithms. In parallel, T-cell receptor β sequencing was performed to detect T-cell clonal expansions in patient-matched primary tumors and TILN. TIL reactivity to tumor-associated antigens and neoantigens was determined in vitro by interferon γ ELISA and flow cytometry. Results: Tumor-infiltrating T cells were evident in all thyroid tumors and readily expanded ex vivo. Shared clones were present in primary thyroid tumors and matched TILN in all patients tested, constituting 1% to 10% of the sequenced clones in 6/8 patients. T-cell reactivity to thyroid tissue-specific proteins, thyroid peroxidase and thyroglobulin, was observed in 84.6% (11/13) and 69.2% (9/13) patients, respectively. A BrafV600E-specific T-cell response was evident in 80% (4/5) BrafV600E+ patients. T cells reactive to gene fusion-derived neoantigens were detected in patients with TPR-NTRK1+ and CCDC6-RET+ thyroid cancer. Conclusion: Our studies confirm the presence of tumor antigen-specific T cells in patients with thyroid cancer and encourage further exploration of T cell-targeted immunotherapies for patients with progressive, treatment refractory thyroid cancer.
- 22 November 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , e1289-e1301
Open AccessTumor-infiltrating T Lymphocytes Recognize Thyroid-specific Proteins and Neo-antigens in Follicular Cell-derived Thyroid Cancers
Background: Thyroid cancers are among the growing list of cancer types that are resistant to immune-checkpoint inhibitor monotherapy. Although T-cell infiltration is common in follicular cell-derived thyroid cancers, tumor mutation burden is low. The antigenic potential of thyroid cancers is unknown. Methods: To investigate the anti-tumor T-cell response in thyroid cancer, we expanded tumor-infiltrating lymphocytes (TIL) from primary thyroid tumors and tumor-involved lymph nodes (TILN). Putative neoantigens and both tissue-associated and tumor-associated antigens were identified by targeted sequencing and RNA-seq. HLA typing was performed for all patients, and neoantigen binding potential was predicted for each patient using NetMHCpan 4.1 and NetMHCIIpan 4.0 algorithms. In parallel, T-cell receptor β sequencing was performed to detect T-cell clonal expansions in patient-matched primary tumors and TILN. TIL reactivity to tumor-associated antigens and neoantigens was determined in vitro by interferon γ ELISA and flow cytometry. Results: Tumor-infiltrating T cells were evident in all thyroid tumors and readily expanded ex vivo. Shared clones were present in primary thyroid tumors and matched TILN in all patients tested, constituting 1% to 10% of the sequenced clones in 6/8 patients. T-cell reactivity to thyroid tissue-specific proteins, thyroid peroxidase and thyroglobulin, was observed in 84.6% (11/13) and 69.2% (9/13) patients, respectively. A BrafV600E-specific T-cell response was evident in 80% (4/5) BrafV600E+ patients. T cells reactive to gene fusion-derived neoantigens were detected in patients with TPR-NTRK1+ and CCDC6-RET+ thyroid cancer. Conclusion: Our studies confirm the presence of tumor antigen-specific T cells in patients with thyroid cancer and encourage further exploration of T cell-targeted immunotherapies for patients with progressive, treatment refractory thyroid cancer.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Myeloid subset frequency in peripheral blood before and on treatment
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Myeloid subset frequency in peripheral blood before and on treatment
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Table 1. Representativeness of Study Participants Supplementary Table 2. Adverse Events (regardless of attribution) Supplementary Table 3. Archival Tumor Biomarker Analyses in Cohort 1 Supplementary Table 4. Archival Tumor Biomarker Analyses in Cohort 2 Supplementary Table 5. Peripheral Blood Biomarker Analyses in Cohort 1 Supplementary Table 6. Peripheral Blood Biomarker Analyses in Cohort 2 Supplementary Table 7. Mutations in Cohort 1 Supplementary Table 8. Mutations in Cohort 2
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Supplementary Table 1. Representativeness of Study Participants Supplementary Table 2. Adverse Events (regardless of attribution) Supplementary Table 3. Archival Tumor Biomarker Analyses in Cohort 1 Supplementary Table 4. Archival Tumor Biomarker Analyses in Cohort 2 Supplementary Table 5. Peripheral Blood Biomarker Analyses in Cohort 1 Supplementary Table 6. Peripheral Blood Biomarker Analyses in Cohort 2 Supplementary Table 7. Mutations in Cohort 1 Supplementary Table 8. Mutations in Cohort 2
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Tumor density of CD8 T cells and myeloid subsets in DTC tumors
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Tumor density of CD8 T cells and myeloid subsets in DTC tumors
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Purpose:Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients.Patients and Methods:We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days.Results:In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1.Conclusions:Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Purpose:Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients.Patients and Methods:We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days.Results:In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1.Conclusions:Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Purpose:Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients.Patients and Methods:We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days.Results:In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1.Conclusions:Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Purpose:Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients.Patients and Methods:We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days.Results:In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1.Conclusions:Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
NLR and MLR before and on treatment
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
NLR and MLR before and on treatment
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Increased HED and HLA diversity are not associated with improved PFS
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Increased HED and HLA diversity are not associated with improved PFS
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
NLR and MLR before and on treatment
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
NLR and MLR before and on treatment